Update Reimbursement Scheme Elvanse®
TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg will be extended to adults from 18 years old and above indicated for the treatment of attention deficit hyperactivity disorder (ADHD) with pre-existing symptoms of ADHD in childhood.
Conditions
The Personal Contribution that is demonstrably charged to the patient by the health insurer for Elvanse® is fully reimbursed with a maximum of € 250 per patient per year. Therefore, the patient can submit a claim with TBR Netherlands.